Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ: MDGL · IEX Real-Time Price · USD

287.24

+8.11 (2.91%)

At close: Jul 19, 2024, 4:00 PM

294.00

+6.76 (2.35%)

Pre-market: Jul 22, 2024, 4:17 AM EDT

Madrigal Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2004
Selling, General & Admin	172.76	108.15	48.13	37.32	21.86	22.65	Upgrade
Research & Development	281.43	272.35	245.44	205.16	184.81	72.32	Upgrade
Operating Expenses	454.2	380.5	293.57	242.48	206.67	94.97	Upgrade
Operating Income	-454.2	-380.5	-293.57	-242.48	-206.67	-94.97	Upgrade
Interest Expense / Income	14.21	12.71	3.96	0	0	0	Upgrade
Other Expense / Income	-24.14	-19.58	-2.19	-0.64	-4.43	-11.02	Upgrade
Pretax Income	-444.28	-373.63	-295.35	-241.85	-202.24	-83.95	Upgrade
Net Income	-444.28	-373.63	-295.35	-241.85	-202.24	-83.95	Upgrade
Shares Outstanding (Basic)	20	19	17	17	15	15	Upgrade
Shares Outstanding (Diluted)	20	19	17	17	15	15	Upgrade
Shares Change	9.97%	9.05%	3.64%	7.05%	0.34%	4.04%	Upgrade
EPS (Basic)	-23.13	-19.99	-17.23	-14.63	-13.09	-5.45	Upgrade
EPS (Diluted)	-23.13	-19.99	-17.23	-14.63	-13.09	-5.45	Upgrade
Free Cash Flow	-391.12	-325.71	-225.07	-184.13	-157.9	-41.8	Upgrade
Free Cash Flow Per Share	-19.55	-17.43	-13.13	-11.13	-10.22	-2.71	Upgrade
EBITDA	-429.49	-360.39	-290.92	-241.44	-201.77	-83.84	Upgrade
Depreciation & Amortization	0.57	0.53	0.47	0.41	0.47	0.11	Upgrade
EBIT	-430.06	-360.92	-291.39	-241.85	-202.24	-83.95	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).